Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Veradermics, Inc issued 300,000 shares of warrant to entities affiliated with Suvretta Capital for $99.99999 per Pre-Funded Warrant.
- Security
- warrant
- Shares
- 300,000 shares
- Purchaser
- entities affiliated with Suvretta Capital
- Consideration
- $99.99999 per Pre-Funded Warrant
Exact text from the filing
the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Veradermics, Inc entered into Purchase Agreement with certain entities affiliated with Suvretta Capital valued at approximately $30.0 million (effective 2026-04-29).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain entities affiliated with Suvretta Capital
- Value
- approximately $30.0 million
- Effective
- 2026-04-29
Exact text from the filing
On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million
View on SEC.gov